Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

NCT03501979 PHASE2 TERMINATED Results posted

A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

Details

Lead sponsor	University of Alabama at Birmingham
Phase	PHASE2
Status	TERMINATED
Enrolment	17
Start date	Wed Feb 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Metastatic Breast Cancer
• Leptomeningeal Disease

Interventions

• Tucatinib
• Trastuzumab
• Capecitabine

Countries

United States